| Study Period | 2020 - 2030 |
| Market Size (2025) | USD 44.96 Million |
| Market Size (2030) | USD 78.82 Million |
| CAGR (2025 - 2030) | 11.88 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Gene-Editing Tools For Non-Human Primates Market Analysis
The Gene-Editing Tools For Non-Human Primates Market size is estimated at USD 44.96 million in 2025, and is expected to reach USD 78.82 million by 2030, at a CAGR of 11.88% during the forecast period (2025-2030).
The major factors driving the studied market are the growing advancements in gene editing technologies, rising investment in biotechnology research, increasing demand for personalized medicine, growing prevalence of genetic disorders, and growing strategic activities by key players in the market.
The growing prevalence of genetic disorders such as sickle cell anemia and cystic fibrosis is expected to increase the demand for effective research animal models to study these conditions. Non-human primates offer genetic and physiological similarities to humans, making them crucial for developing and testing gene editing interventions for developing novel gene therapeutics, ultimately driving the studied market over the forecast period. For instance, as per the Cystic Fibrosis Foundation's updated data from January 2024, there are close to 40,000 children and adults living with cystic fibrosis in the United States in 2023. Hence, the significant prevalence of genetic diseases is expected to increase the utilization of genetic tools in non-human primates for the development of novel therapeutics for the treatment of genetic disorders, which ultimately drive the studied market over the forecast period.
Furthermore, the increasing investment in genetic tools for developing novel drugs is also expected to increase the utilization of these tools in non-human primates, which ultimately drives the studied market over the forecast period. For instance, in October 2024, the National Institutes of Health granted USD 14 million in funding for gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children’s Hospital of Philadelphia (CHOP). This funding will be specifically used to develop therapies for urea cycle disorders, which impact roughly 1 in every 35,000 children. Hence, such investments are expected to increase the utilization of gene-editing tools in non-human primates for the development of novel therapeutics, which ultimately drive the studied market over the forecast period.
Moreover, the increasing research activities in the field of gene editing are also expected to increase the utilization of these technologies in non-human primates, which ultimately drive the studied market over the forecast period. For instance, in October 2023, Prime Medicine, Inc., a biotechnology company committed to delivering one-time curative genetic therapy, reported the new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct one of the most prevalent disease-causing mutations of glycogen storage disease 1b(GSD1b) in non-human primates (NHP) and mouse models. The data were presented today at the European Society of Gene and Cell Therapy (ESGCT) 2023 Congress in Brussels, Belgium. Hence, such research activities are expected to increase the utilization of gene-editing tools in non-human primates, which ultimately drives the studied market over the forecast period.
Thus, the increasing prevalence of genetic diseases such as sickle cell anemia, increasing investment in genetic tools, and growing research activities in the field of gene-editing are expected to drive the studied market over the forecast period. However, the lack of ethical concerns regarding the use of non-human primates is expected to restrain the studied market over the forecast period.
Gene-Editing Tools For Non-Human Primates Market Trends
CRISPR/Cas9 Segment is Expected to Hold Significant Market Share Over the Forecast Period.
CRISPR-Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding, or altering sections of the DNA sequence. The major factors driving the segment growth are increasing investment in the CRIPR/Cas9 technology and strategic activities by the key players in the market.
The increasing clinical applications of CRISPR-Cas9 technology raise the demand for an efficient understanding of various diseases, which helps develop novel drugs and drives the studied segment over the forecast period. For instance, according to an article published in the Retrovirology in August 2024, CRISPR-Cas9 gene editing technologies present opportunities to clarify non-human primates (NHP) HIV models for investigating genetic factors that affect HIV replication and designing cellular therapies that exploit genetic barriers to HIV infections, including engineering mutations into CCR5 and conferring resistance to HIV/simian immunodeficiency virus (SIV) infections. Hence, due to the various applications of CRISPR-Cas9 in understanding diseases such as HIV and developing novel drugs, it is expected to accelerate the studied segment over the forecast period.
Furthermore, the increasing strategic activities, such as product launches by key players, are also expected to accelerate the research activities in the gene-editing field by using the CRISPR-Cas9 technology in the non-human primates, which ultimately drive the studied market over the forecast period. For instance, in December 2023, Vertex and CRISPR Therapeutics reported the authorization of the CRISPR/Cas9 Gene-edited therapy, CASGEVY(exagamglogene autotemcel), by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia (TDT). CASGEVY was authorized for the treatment of eligible patients 12 years of age and older with SCD with recurrent vaso-occlusive crises (VOCs) or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. Hence, the increasing accessibility of such applications is expected to raise the utilization of ABA therapy in the treatment of anxiety and drive the studied market over the forecast period.
Hence, launching such products increases the utilization of gene-editing tools in non-human primates for research purposes, which ultimately drives the studied market over the forecast period. Thus, increasing clinical applications of CRISPR-Cas9 technology and rising strategic activities such as products by the key players increase the utilization of CRIPSR-Cas9 technology in the non-human primates for research activities, which ultimately studied segments over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold the Significant Market Share Over the Forecast Period.
The gene-editing tools for non-human primates market in North America are driven by factors such as the advanced research infrastructure, rising prevalence of genetic diseases, growing interest in personalized medicine, technological advancements in gene-editing tools, and rising strategic activities by the key players in the market.
The rising technological advancements in gene-editing technology are expected to increase the accessibility of this technology for various research purposes, which ultimately drives the studied market over the forecast period. For instance, in December 2023, Tome Biosciences, a biotechnology startup, received USD 213 million in venture funding from Arch Venture Partners, GV, and Longwood Fund. This funding was used to develop a new gene editing technology called programmable genomic integration, or PGI, and based on research licensed from the Massachusetts Institute of Technology, the approach is designed to insert varying sizes of genetic material anywhere in the genome without damaging or breaking DNA. Hence, such technological advancements are expected to increase the utilization of gene-editing tools in non-human primates to develop novel therapeutics, ultimately driving the studied market over the forecast period.
Furthermore, the increasing strategic activities, such as launching novel products by key players, increase the accessibility of the applied behavior analysis therapy, ultimately driving the studied market over the forecast period. For instance, in May 2024, Latus Bio, Inc., a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), reported its launch and an initial close of USD 54 million in Series A financing. Latus’s proprietary technologies enable the paralleled and unbiased screening of novel AAV capsids directly in non-human primates. In these preclinical NHP models, Latus’s capsid variants demonstrated high gene expression in precise CNS locations with target cell specificity and minimal-to-no off-tissue activity. Thus, such strategic activities are expected to drive the studied market over the forecast period.
Hence, the rising technological advancements in the gene-editing field and growing strategic activities by the key players in the market are expected to increase the utilization of these technologies in the development of novel therapeutics, which ultimately drive the studied market over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Gene-Editing Tools For Non-Human Primates Industry Overview
The gene-editing tools for the non-human primates market are semi-consolidated due to many global and regional players in the field. The major players in the market are adopting various strategic activities such as mergers, collaborations, and raising funds for new solutions development. Some of the key players in the market are Editas Medicine, Intellia Therapeutics, Cellectis, Regeneron Pharmaceuticals, and Sangamo Therapeutics, among others players.
Gene-Editing Tools For Non-Human Primates Market Leaders
-
Editas Medicine
-
Intellia Therapeutics
-
Cellectis
-
Regeberon Pharmaceuticals
-
Sangamo Therapeutics
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Gene-Editing Tools For Non-Human Primates Market News
- January 2024: Tome Biosciences, Inc., a prominent company specializing in programmable genomic integration (PGI), acquired Replace Therapeutics Inc., a private biotechnology firm focused on developing an innovative PGI method for precise insertion and deletion of small DNA sequences. Replace's technology harnesses the site-specific precision of CRISPR/Cas9 and the writing capabilities of the DNA ligase enzyme to deftly manipulate small DNA sequences.
- November 2023: Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics, reported the hat the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Gene-Editing Tools For Non-Human Primates Industry Segmentation
As per the scope of the report, gene editing is a type of genetic engineering in which DNA is inserted, deleted, modified, or replaced in the genome of cells or organisms. This technique can be used, for example, to modify genetic information within an non-human primate to introduce new characteristics, or to remove specific regions of genomes provide a suitable model for the study of human disease. The gene-editing tools for non-human primates’ market is segmented into technology, application, end-user, and geography. By technology, the market is segmented into CRISPR/Cas9, Transcription Activator-Like Effectror Nucleases (TALENs), Zinc Finger Nucleases (ZFNs), and others. By application, the market is segmented into biomedical research, transgenic model development, pharmaceutical development, and gene therapy research. By end user, the market is segmented into research institutions and biotechnology companies. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers the value (in USD) for the above segments.
| By Technology | CRISPR/Cas9 | ||
| Transcription Activator-Like Effectror Nucleases (TALENs) | |||
| Zinc Finger Nucleases (ZFNs) | |||
| Others | |||
| By Application | Biomedical Research | ||
| Transgenic Model Development | |||
| Pharmaceutical Development | |||
| Gene Therapy Research | |||
| By End User | Research Institutions | ||
| Biotechnology Companies | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Gene-Editing Tools For Non-Human Primates Market Research FAQs
How big is the Gene-Editing Tools For Non-Human Primates Market?
The Gene-Editing Tools For Non-Human Primates Market size is expected to reach USD 44.96 million in 2025 and grow at a CAGR of 11.88% to reach USD 78.82 million by 2030.
What is the current Gene-Editing Tools For Non-Human Primates Market size?
In 2025, the Gene-Editing Tools For Non-Human Primates Market size is expected to reach USD 44.96 million.
Who are the key players in Gene-Editing Tools For Non-Human Primates Market?
Editas Medicine, Intellia Therapeutics, Cellectis, Regeberon Pharmaceuticals and Sangamo Therapeutics are the major companies operating in the Gene-Editing Tools For Non-Human Primates Market.
Which is the fastest growing region in Gene-Editing Tools For Non-Human Primates Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Gene-Editing Tools For Non-Human Primates Market?
In 2025, the North America accounts for the largest market share in Gene-Editing Tools For Non-Human Primates Market.
What years does this Gene-Editing Tools For Non-Human Primates Market cover, and what was the market size in 2024?
In 2024, the Gene-Editing Tools For Non-Human Primates Market size was estimated at USD 39.62 million. The report covers the Gene-Editing Tools For Non-Human Primates Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Gene-Editing Tools For Non-Human Primates Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Gene-Editing Tools For Non-Human Primates Industry Report
Statistics for the 2025 Gene-Editing Tools For Non-Human Primates market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gene-Editing Tools For Non-Human Primates analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
